THERALASE TECHNOLOGIES INC /FI
No SEC Form 4 filings for $TLTFF in the last 30 days.
Theralase Technologies Inc. (TSXV: TLT, OTCQB: TLTFF) said it granted 7,000,000 stock options to eligible participants under its stock option plan. Options are exercisable at C$0.265 per common share, vest over three years, and expire five years after grant, subject to TSX Venture Exchange acceptance.
Theralase Technologies Inc. (TSXV: TLT, OTCQB: TLTFF) said it granted 7,000,000 stock options under its stock option plan. Options are exercisable at C$0.265 per share, vest over three years, and expire five years after grant, subject to TSX Venture Exchange acceptance.
Over the past 7 days, alphai's AI scored 2 news stories mentioning TLTFF (THERALASE TECHNOLOGIES INC /FI). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Routine equity incentive grant that can modestly affect dilution expectations, but provides no new clinical or financial guidance.
Routine equity-compensation grant that can modestly affect dilution expectations and near-term sentiment, but provides no new clinical or financial guidance.
alphai scores every news story that mentions TLTFF with an AI model for sentiment and relevance, and aggregates insider trades from THERALASE TECHNOLOGIES INC /FI's SEC EDGAR Form 4 filings. Figures refresh continuously.
Theralase Technologies Inc. (TSXV: TLT, OTCQB: TLTFF) said it granted 7,000,000 stock options to eligible participants under its stock option plan. Options are exercisable at C$0.265 per common share, vest over three years, and expire five years after grant, subject to TSX Venture Exchange acceptance.
2 min readTheralase Technologies Inc. (TSXV: TLT, OTCQB: TLTFF) said it granted 7,000,000 stock options under its stock option plan. Options are exercisable at C$0.265 per share, vest over three years, and expire five years after grant, subject to TSX Venture Exchange acceptance.
2 min read